| Drug Name |
Granisetron |
| Drug ID |
BADD_D01040 |
| Description |
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. |
| Indications and Usage |
For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation). |
| Marketing Status |
approved; investigational |
| ATC Code |
A04AA02 |
| DrugBank ID |
DB00889
|
| KEGG ID |
D04370
|
| MeSH ID |
D017829
|
| PubChem ID |
5284566
|
| TTD Drug ID |
D0J5KF
|
| NDC Product Code |
14778-0202; 47426-101; 63850-7308; 42747-726; 53104-7609; 55111-841; 55718-117; 54871-1091 |
| UNII |
WZG3J2MCOL
|
| Synonyms |
Granisetron | 1-Methyl-N-(endo-9-Methyl-9-Azabicyclo(3.3.1)non-3-yl)-1H-Indazole-3-Carboxamide | Kytril | BRL-43694A | BRL 43694A | BRL43694A | BRL-43694 | BRL 43694 | BRL43694 | Granisetron Hydrochloride | Hydrochloride, Granisetron | Granisetron Monohydrochloride | Monohydrochloride, Granisetron |
